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Eighteen cases of chikungunya virus infection in trav-
ellers returning from Myanmar were reported to the 
GeoSentinel Surveillance Network, its subnetwork 
EuroTravNet and TropNet in 2019, reflecting an ongo-
ing local outbreak. This report reinforces the impor-
tance of travellers as sentinels of emerging arboviral 
outbreaks and highlights the importance of vigilance 
for imported cases, due to the potential for dissemina-
tion of the virus into areas with competent local vec-
tors and conducive environmental conditions.
In early October 2019, a GeoSentinel Surveillance 
Network site in Madrid, Spain, identified two 
patients with chikungunya virus (CHIKV) infection 
who had recently visited Myanmar. Rapid outreach to 
GeoSentinel sites (including EuroTravNet), TropNet and 
Laos external collaborators identified 16 additional 
infected travellers who acquired CHIKV infection in 
Myanmar during 2019.
According to a newspaper report, the Myanmar 
Department of Public Health identified an outbreak of 
CHIKV infection in 2019, mainly in Nay Pyi Taw, Kachin 
State, and Tanintharyi Region, Myanmar [1]. In the pre-
vious 8 years however, no cases of CHIKV infection had 
been officially reported in the country [2,3].
We describe travellers with imported CHIKV infection 
from Myanmar who were diagnosed in 2019 (January to 
November) and identified at GeoSentinel, EuroTravNet 
and TropNet sites. Some epidemiological and clinical 
information as well as places visited by the travellers 
are presented.
Case finding
GeoSentinel is a global surveillance network for emerg-
ing infectious diseases that has 68 sites in 28 coun-
tries; EuroTravNet is its European subnetwork; TropNet 
represents a separate European surveillance entity 
represented by 75 specialised tropical medicine cen-
tres in Europe.
For chikungunya surveillance, GeoSentinel follows case 
definitions proposed by the World Health Organization 
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Table 1
Epidemiological and travel characteristics of confirmed and probable chikungunya cases among travellers returning from 




Places visited in Myanmar
Pre-travel 
consultation












1 Japan Yangon Yes




60 Hypertension Jul 2019




25 Atopic dermatitis Aug 2019




45 No Aug 2019
4 Italy Nyaungshwe Yes
Lived in Myamnar 
until Aug 2019 
 
(NA)
60 No Aug 2019
5 Japan Yangon Yes










Yangon, Hpa-An, Moulmein, 
Ye, Mandalay, Bagan, Inle 
lake, Pindaya
Yes
Jul to Aug 2019 
 
(23 days)




Ye, (Mon State), Yangon Unknown
May to Aug 2019 
 
(65 days)
20 No Jul 2019




30 No Aug 2019
9 Spain






55 No Aug 2019
10 Italy
Yangon, Mandalay, Inle 
Lake,
No
Aug to Sep 2019 
 
(12 days)
50 No Sep 2019
11 Italy Yangon, Mandalay, Inle Lake No
Aug to Sep 2019 
 
(12 days)
50 No Sep 2019




50 No Sep 2019
13 Germany






65 Mitral valve disease Feb 2019
14 Germany






30 No Feb 2019
15 Italy Yangon, Bagan, Mandalay No
Jul to Aug 2019 
 
(12 days)
65 Hypertension Jul 2019




55 No Aug 2019
17 Germany







25 No Oct 2019
18 France
Yangon, Mandalay, Bagan, 
Inle Lake
Unknown
Oct to Nov 2019 
 
(15 days)
55 No Oct 2019
F: female; Ig: immunoglobulin; M: male; NA: not assessed; VFR: visiting friends and relatives.
a Age rounded by five.
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(WHO) Regional Office for Southeast Asia [4]. Such 
definitions were used in the current report. A possible 
case was a patient with acute onset of fever >38.5°C and 
severe arthralgia/arthritis not explained by other medi-
cal conditions. A probable case was a patient meeting 
both the previously mentioned clinical criteria and the 
following epidemiological criteria: residing or having 
visited epidemic areas, having reported transmission 
within 15 days prior to the onset of symptoms. A con-
firmed case had to meet one or more of the following 
laboratory criteria, irrespective of the clinical presenta-
tion: (i) virus isolation in cell culture or animal inocu-
lations from acute phase sera, or (ii) presence of viral 
RNA in acute phase sera as demonstrated by RT-PCR, 
or (iii) presence of virus-specific IgM antibodies in sin-
gle serum sample in acute or convalescent stage, or 
(iv) fourfold increase in virus-specific IgG antibody titre 
in samples collected at least 3 weeks apart.
For this study, cases were excluded if they were not 
in Myanmar at the likely time of exposure, which was 
inferred from their date of symptom onset and the typi-
cal incubation period (defined as 3 to 7 days) [5] or if 
the travellers had more than one potential travel desti-
nation exposure based on the incubation period.
 
Description of cases
Epidemiological and clinical details for each patient 
were collected from reporting sites.
The 18 cases reported in the current study had a 
median age of 51 years (range: 19–68 years) and 10 
were male (Table 1). Among the overall cases, one had 
visited friends and relatives in Myanmar at the likely 
time of exposure, two were there on a business trip and 
three were expatriates. The rest of the cases, which 
represented the majority (n = 12), were tourists who 
had experienced a median length of stay of 13 days in 
Myanmar (range: 6–65 days).
The majority of cases were imported to Europe (n = 13) 
and Asia (n = 4), with one case in the Americas. Fewer 
than half (7/16) of travellers with available informa-
tion, received pre-travel advice. Destinations visited in 
Myanmar are shown in the Figure.
Among the 18 cases, acute symptoms reported included 
fever (n = 18), arthralgia (n = 16) and rash (n = 14) (Table 
2). A median of 9.5 days (range: 1–240 days) elapsed 
between symptom onset and diagnosis. Most travel-
lers (n = 13) were identified at reporting sites between 
August and October 2019. Seven cases were confirmed 
by PCR, including five who were also found IgM posi-
tive, and nine cases were confirmed by a positive IgM 
only; the remaining two patients had probable diagno-
ses based on a single IgG positive serology. No acute 
coinfections with other arboviruses were described in 
the 16 patients tested for additional pathogens.
Figure 
Possible places of exposure: destinations visited by 
travellers before chikungunya virus infection, Myanmar, 


















Asterisks represent the places where travellers in the current study 
were possibly exposed to chikungunya virus. Some travellers 
visited the same destinations.


















Clinical and diagnostic characteristics of confirmed and probable chikungunya cases among returning travellers from Myanmar, 2019 (n = 18)




Clinical status as 
at 20 Oct 2019
Chikungunya diagnostic method
Day of diagnosis in 2019 
 





Fever, rash, arthralgias 














Fever, rash, arthralgia 
(wrists, ankles), retro-




































Fever, arthralgia, deep 
asthenia, profuse sweating
Persistent arthralgias 
needing NSAIDs and CT 
(prednisone)






Fever, rash, arthralgia 
(fingers, wrists, 
















6 Fever, ankles oedema

















Fever, rash, chills, 
myalgias, symmetric 
arthralgias (knees, ankles, 
wrists, hands)
Improving with NSAIDs No Improving







Fever, rash, arthralgias 
(ankles, wrists, feet, 
interphalangeal joints in 
hands, bilateral)
Persistent arthralgias 
needing NSAIDs and CT








9 Fever, rash, arthralgia
Persistent arthralgias 
needing NSAIDs and CT
No Improved









Fever, rash, arthralgia, 
diarrhoea, paraesthesia 
lower limbs, swelling 
































Clinical status as 
at 20 Oct 2019
Chikungunya diagnostic method
Day of diagnosis in 2019 
 




















Fever, pruritus, rash, head 




Little light headed 
when exercise








Fever, nausea, arthralgias, 
ankle oedema
Persistent incapacitating 
arthralgias and ankle 













Dengue: NS1−; IgM−, IgG+ 
(multiple exposures 
before, IIFT+ with low titre) 
 
Zika: not tested
14 Fever, rash, arthralgia













Fever, rash, arthralgias 
(wrists, right elbow, 
metacarpophalangeal 
































for CHIK was 
done.
Mild arthralgias in 
fingers and ankles




















Dengue: PCR–; IgM– 
 
Zika: PCR–; IgM–
CT: corticosteroids; IIFT: indirect immunofluorescence test; Ig: immunoglobulin; NSAID: non-steroidal anti-inflammatory drug; NS1: nonstructural 1 protein antigen; RDT: rapid diagnostic test; RT-PCR: real 
time PCR.
Table 2b
Clinical and diagnostic characteristics of confirmed and probable chikungunya cases among returning travellers from Myanmar, 2019 (n = 18)
6 www.eurosurveillance.org
Four patients were hospitalised, and 15 needed non-
steroidal anti-inflammatory drugs; four had corticos-
teroids added to manage symptoms (Table 2). As at 
20 October 2019, fourteen patients still had persistent 
symptoms, predominantly arthralgia.
Discussion
Chikungunya is often a mild self-limited illness, but 
severe and life-threatening complications have been 
described [6]. Persistent polyarthralgia can affect up 
to 40% of infected individuals and may last for months 
or years [7,8]. A high proportion of cases in our case 
series (14 of 18) had persistent sequelae (mainly 
arthralgia) that interfered with their daily life. Given 
the potential for long-term morbidity, the absence of 
a curative treatment or a preventive vaccine, detailed 
pre-travel counselling should focus on mosquito-bite 
prevention, particularly for those at high risk of inca-
pacitating complications such as women older than 40 
years, people with underlying rheumatic diseases, and 
professional athletes [9].
Considering the short duration of stay in different parts 
of Myanmar of many of the currently reported travellers, 
as well as the usual incubation period of chikungunya, 
the specific place where they were infected cannot be 
determined with certainty. Most patients in the case 
series acquired chikungunya from August to October, 
likely due to enhanced vector activity at the end or 
after the monsoon season, which occurs between May 
and August.
CHIKV has been detected in South and South East 
Asia since the 1950s [3], but its current epidemiology 
is poorly understood [10]. In Myanmar, CHIKV infec-
tion was first described in 1973 [11]. Since this time, 
the virus has caused outbreaks in 1998, 2006 and 
2008 [3]. The number of reported cases subsequently 
declined until 2010, when local surveillance identi-
fied the last reported case [3]. Thereafter, from 2011 
to 2018 no CHIKV cases were officially reported in the 
country, however a review of travellers who acquired 
chikungunya in Myanmar in the GeoSentinel database 
from 2000 to October 2019 revealed two cases in 2015 
and 2016, one probable and one confirmed.
In 2019, Myanmar’s National Health Laboratory 
detected chikungunya cases again [1]. During the 
same year, other national surveillance systems also 
identified travellers who acquired chikungunya in 
Myanmar. For example, the Japanese National Institute 
of Infectious Diseases, which systematically tracks 
travellers, detected 28 imported cases of chikungunya 
from Myanmar to Japan [12]. The Italian Arboviriasis 
Surveillance System also detected four imported cases 
in Italy [13]. Our report highlights additional cases of 
exported CHIKV infection from Myanmar.
Little is known about factors contributing to the multi-
ple detections of CHIKV infections in or from Myanmar 
in 2019. While aside from this year, no cases within the 
country had been officially observed since the end of 
2010, the detection of exported cases in 2015 and 2016 
could suggest that CHIKV might have continued to cir-
culate in Myanmar after 2010. Myanmar’s disease sur-
veillance system includes a Central Epidemiology Unit 
(CEU) and several vertical control programmes [14]. 
Certain areas of the country are, however, difficult to 
access and there could have been underreporting due 
to limitations of surveillance capacity.
Myanmar has geographical and epidemiological char-
acteristics that put it at risk for CHIKV epidemics: a 
highly susceptible population [15], a long border with 
two large neighbouring endemic countries (India and 
Thailand) with cross-border population movement for 
trade and travel purposes [16], and competent vectors 
(both Aedes aegypti and Ae. albopictus) [17]. According 
to the Thai Ministry of Public Health, CHIKV is cur-
rently circulating in Thailand with an increasing inci-
dence: as at 30 October 2019, the country has reported 
8,744 cases this year [18]. Coincidentally, GeoSentinel 
recently documented a rise in the number of travel-
associated CHIKV infections from Thailand [19]. Without 
further epidemiological and phylogenetic evidence, it 
remains difficult to establish whether any links exist 
between cases in Thailand and those in Myanmar.
It should be noted that Myanmar is an increasingly 
popular tourist destination, with more than 3.5 million 
visitors in 2017 [20]. Hence, although we report more 
cases exported from Myanmar in 2019 than in previ-
ous years, a surge in tourism to this country may have 
led to an apparent increase of the number of exported 
cases. GeoSentinel data are moreover not population-
based so rates or risk estimates cannot be derived. 
Also, diagnostics depend on local site interpretation 
and reporting.
Imported CHIKV infection by viraemic travellers return-
ing to their home countries raises the possibility of 
virus spread to these countries if competent vectors 
are present, mainly in hot seasons, as European  Ae. 
albopictus  is affected by seasonal temperature and 
undergoes a winter diapause [21]. There is also a 
potential risk of transmission by other routes, such as 
blood donation [22]. In Europe, some countries (Italy 
in 2007 and 2017, France in 2010, 2014 and 2017) have 
experienced autochthonous transmission of CHIKV 
through viraemic travellers [23]. Surveillance and early 
detection of both imported and autochthonous CHIKV 
infections is therefore relevant in areas with competent 
vectors, as well as close vector monitoring and rapid 
public health response.
This report of imported CHIKV infections reinforces 
the importance of travellers as sentinels of local out-
breaks, particularly in settings with limited public 
health surveillance and reporting infrastructure.
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